Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

T. Intermesoli,F. Castagnetti,S. Soverini,A. Bussini,O. Spinelli,A. Gnani,R. Bassan,G. Rosti
DOI: https://doi.org/10.1016/j.leukres.2011.09.002
Abstract:
What problem does this paper attempt to address?